Bengest-1 (Solution for injection). Pharmacological action for the development and maintenance of female, genital and extragenital secondary sexual characteristics. Each milliliter contains one milligram of estradiol benzoate .
Morphological changes
The estrogens produce three morphological changes in the female genital organs: edema , hyperemia and cell proliferation (both epithelial and muscle). In the breasts during puberty , estrogens determine the growth and development of the milk ducts and alveoli and inhibit milk secretion . The myometer under the action of this hormone increases its contractility and excitability.
Action
In the breasts during puberty, estrogens determine the growth and development of the milk ducts and alveoli and inhibit milk secretion.
The myometer under the action of this hormone increases its contractility and excitability. In animals, the administration of estrogen stimulates the production of gonadotropins by the anterior lobe of the pituitary gland , which restore the normal estrous cycle in a female with anestrus. The injection of estrogens causes thickening of the epithelial tissue and then cornification, that is, first nucleated epithelial cells-proestrus and then keratinized cells without nucleus-oestrus.
They stimulate the development of the entire genital system; thus they provoke the development of the uterine muscle and in the mucosa (endometrium) they produce cell proliferation . In the vagina, the administration of estrogens produces thickening of the epithelium and cornification. They produce an increase in the spontaneous motility of the uterus and uterine muscle (Miómetro). Milk secretion is inhibited by inhibition of prolactin secretion by the anterior pituitary .
Indications
Cases of postpartum metaphylaxis, treatment of endometritis , anestrus and early diagnosis of non-pregnancy in cattle.
Contraindications
Contraindicated in animals with malignant tumors of the uterus or breasts, pregnancy, lactation (since it suppresses it), severe liver and kidney disease, arterial or venous thromboembolic disease. In pregnancy, estrogens at a high dose in animals can cause abortion at the beginning of pregnancy, by modification of the endometrium that makes implantation or development of the egg impossible, and at the end of it due to increased uterine motility.
It should not be used in pregnant animals as it causes fetal malformations in the genitourinary system and bone marrow depression.
Precautions
Treatment should be supplemented with a sequential administration of a progestogen to protect the endometrium since prolonged estrogen therapy increases the risk of endometrial hyperplasia and carcinoma. In cases of not observing a manifest improvement of the animal, reconsider the diagnosis and treatment. Treated animals must be observed for at least half an hour after administration of the product.
Adverse reactions
Prolonged estrus, decreased milk production , development of follicular cysts. These effects are related to overdose.
Posology
Single dose intramuscular route used in bovine species: Puerperium metaphylaxis : 3 mg (3 mL) at 12 ± 1 day postpartum, reduces the incidence of endometritis, anestrus and parturition-gestation interval. Endometritis: 3 mg (3 ml). The diagnosis of recovery at 7 days above 70%. Anestrus: 0.5 mg (0.5 ml). Stimulates the restart of ovarian activity, greater efficiency in total heat. Early prognosis of non-pregnancy: 0.5 mg (0.5 ml) at 20 ± 1 day post artificial insemination, the effectiveness is 100%. The dose is for single administration.